Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyHodgkin LymphomaIndolent LymphomasT-Cell and NK-Cell NeoplasmsTransplantationDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupCD20+ICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C83.7C84.4C84.6C84.7C85.2C86.1C86.2C86.5C88.0-C91.0-C91.1-C94.7-MeSHLymphoma, Large-Cell, AnaplasticLymphoma, Mantle-CellLymphoma, T-Cell, PeripheralPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceEPCO(0.16/0.8/48), DLBCL, C1 (PID2486) -|- C2-3 (PID2487) -|- C4-9 (PID2488) -|- C10+ (PID2489)EPCORE NHL-2: EPCO(0.16/0.8/3/48)/GEMC1000/OXAL100, DLBCL, C1 (PID2927) -|- C2-3 (PID2928) -|- C4 (PID2929) -|- C5-9 (PID2930) -|- C10+ (PID2489)IXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)MOSU(1/2/60), B-NHL, C1 (PID2105) -|- C2 (PID2106) -|- C3+ (PID2107)R-ACVBP (RITU375/DOXO75/CYCL1200/VIND2/BLEO10/PRED60) ind., DLBCL A (PID340) -|- cons., B (PID341) -|- cons., C (PID342) -|- cons., D (PID343)R-CHOP 14 (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1-6 (PID112) -|- RITU375, C7-8 (PID1448)R-CHOP 14 smart (RITU375/CYCL750/DOXO50/VNCR2/PRED100), DLBCL, C1 (PID926) -|- C2 (PID929) -|- C3 (PID930) -|- C4 (PID929) -|- C5 (PID930) -|- C6 (PID929) -|- C7+ (PID75)R-ICE (RITU375/ETOP100/CRBP5/IFOS5), DLBCL, C1 (PID348) -|- C2+3 (PID349)STUDY - levelSTUDY OPTIMAL, Arm F-ASTUDY OPTIMAL, Arm F-BChemotherapyChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEpcoritamabEtoposideFludarabineGemcitabineIfosfamideMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabOxaliplatinPixantronPrednisoloneRituximabVincristineVincristine liposomalVindesineChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEpcoritamabEtoposideFludarabineGemcitabineIfosfamideMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabOxaliplatinPixantronPrednisoloneRituximabVincristineVincristine liposomalVindesineChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEpcoritamabEtoposideFludarabineGemcitabineIfosfamideMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabOxaliplatinPixantronPrednisoloneRituximabVincristineVincristine liposomalVindesineChemo-substanceBendamustineBleomycinCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin liposomalEpcoritamabEtoposideFludarabineGemcitabineIfosfamideMelphalanMethotrexateMethylprednisoloneMitoxantroneMosunetuzumabNivolumabOxaliplatinPixantronPrednisoloneRituximabVincristineVincristine liposomalVindesineNo. Substances123456 RadiotherapySupportive therapySupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFilgrastimFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateNo. Substances134567891011Protocol classificationTherapy classificationalternativecurrent standardolder age and/or reduced general conditionstudy analogStudy protocol, currentIntensityDose intensifiedStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleThird line Therapy phaseConsolidationInductionPre-phaseReinductionSalvageTherapy intentioncurativedisease controlpalliativeRisksAlopeciaAnemia Hb below 8g/dlAstheniaBleedingCardiotoxicityCytokine Release SyndromeDiarrheaEdemaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHeadacheHyperglycemiaHypertensionHypokalemiaHypophosphatemiaIncrease AminotransferasesInfectionsLymphopeniaNeuropathyNeurotoxicityNeutropeniaOral MucositisPainPneumoniaPyrexiaRenal FailureSepsisThrombocytopenia below 50 000/µlTumor Lysis Syndrome only studiesPublicationAuthorAydin SBudde LECoiffier 2002Davies AEl Gnaoui TGisselbrecht CHeld GHerbrecht RKirschey SLiu E Luminari SMartin APettengell RPeyrade FPfreundschuh MRodriguez MARécherSchmitz NTessoulin BThieblemont CVelasquez WSWeidmann EDiseaseAggr. B-NHL, Rezidiv oder therapierefraktäraggr. B-NHL incl. DLBCL, nach Rezidiv oder bei fehlendem CR unter Erstlinie mit CHOP, ECOG 0-1Aggr. B-NHL über 80 Jahre oder unter 80 mit KI gegen R-CHOP, ErstlinieAggr. oder de novo transf. B-NHL, Rezidiv - Drittlinie und höher, ECOG 0-2aggressive, CD 20+ B-NHL, 18-60 Jahre, Erstlinie, ECOG 0-3aggressive CD20+ B-NHL, 61-80 Jahre, ECOG 0-1Aggressives B-NHL, 61-80 Jahre, Erstlinie, ECOG 0-2B-NHL, refraktär oder rezidivierend, ohne Eignung zur HochdosistherapieB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieB-Non-Hodgkin-Lymphom/Hodgkin LymphomCoiffier 2002: DLBCL, 60-80 Jahre, ECOG 0-2, Erstlinie , Cunningham 2013: DLBCL, ab 18 Jahren, ECOG 0-3, Erstlinie.DLBCL, Erstlinie, bis 59 JahreDLBCL, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieDLBCL, Stadium II - IV, CD20+, Erstlinie, ECOG 0-2DLBCL, über 80 Jahre, ECOG 0-2, ErstlinieDLBCL Stadium I-IV, älter als 60 Jahre, Erstlinie, ECOG 0-2Lymphom, rezidiviert oder therapierefraktärLymphom, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieNon-Hodgkin-Lymphom / Hodgkin Lymphomrezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2rezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2rezidiviertes oder refraktäres B-NHL, mindestens zwei vorherige systemische BehandlungenRezidiviertes und therapierefraktäres DLBCL, follikuläres Lymphom °IIIB, mind. 2 Vortherapien, ECOG 0-2OriginAbteilung für Hämatologie, Universität Duisburg-Essen, DeutschlandCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCity of Hope National Medical Center, Duarte, CADepartment of Clinical Hematology, Henri Mondor Hospital, Créteil, FrankreichDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Haematology, St George's Hospital, University of London, EnglandDepartment of Oncology and Hematology, Hôpital de Hautepierre, Strasbourg, France, PIX203 trialDSHNHL 2002-1DSHNHL 2009-1, OPTIMAL > 60Euro18-trial Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena Cancer Center, ItalyGEL/TAMO cooperative groupe, SpanienGerman High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL), RICOVER-60Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigatorsGroupe d'Etude des Lymphomes de l'Adulte (GELA) investigators LNH03-2BHopital Saint-Louis, Hemato-oncologie, Universite de Paris, Paris, FranceHopital Saint Louis, Paris, Frankreich, CORAL StudieHospices Civils de Lyon, Université Claude Bernard, FrankreichInternal Medicine I Saarland University Medical School, DSHNHL 2015-1Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt am Main, DeutschlandNantes Medical University, Nantes, FranceSection of Lymphoma, M.D. Anderson Cancer Center, Houston, TXUniversity of Texas M.D. Anderson Cancer Center, HoustonUniversity of Texas M.D. Anderson Cancer Center, Houston, USAUniversitätsklinikum des Saarlandes, Homburg, SMARTE-R-CHOP-14 Trial, DSHNHLProtocols in Revision 48 protocols foundDHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346 V1.0)Epcoritamab (0.16/0.8/48), diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID2486 V1.1)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 10+ (PID2489 V1.2)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, Cycle 2-3 (PID2487 V1.2)Epcoritamab 48, diffuse large B-non-Hodgkin Lymphoma, cycle 4-9 (PID2488 V1.2)ESHAP - Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, Non-Hodgkin Lymphoma. (PID2348 V1.0)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471 V2.0)MINE (Ifosfamide 1.33 / Mitoxantrone 8 / Etoposide 65), B-non-Hodgkin Lymphoma. (PID2389 V1.0)Mosunetuzumab (1/2/60), B-Non-Hodgkin Lymphoma, cycle 1 (PID2105 V1.0)Mosunetuzumab 30, B-Non-Hodgkin Lymphoma, cycle 3+ (PID2107 V1.1)Mosunetuzumab 60, B-Non-Hodgkin lymphoma, cycle 2 (PID2106 V1.1)Pixantron 50, diffuse large B-non-Hodgkin Lymphoma (PID360 V1.1)R- Benda - Rituximab 375 / Bendamustine 120, diffuse large B-non-Hodgkin Lymphoma (PID338 V1.1)R- ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID348 V1.1)R- ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, diffuse large B-non-Hodgkin Lymphoma, cycle 2+3 (PID349 V1.2)R-ACVBP - Cytarabine 100 consolidation, diffuse large B-non-Hodgkin Lymphoma Part D (PID343 V1.0)R-ACVBP - high-dose Methotrexate 3000, diffuse large B-non-Hodgkin Lymphoma, consolidation, part B (PID341 V1.2)R-ACVBP - Rituximab 375 / Doxorubicin 75 / Cyclophosphamide 1200 / Vindesin 2 / Bleomycin 10 / Prednisolone 60, induction, diffuse large B-non-Hodgkin Lymphoma Part A (PID340 V1.0)R-ACVBP - Rituximab 375 / Ifosfamide 1.5 / Etoposide 300 consolidation, diffuse large B-non-Hodgkin Lymphoma Part C (PID342 V1.0)R-ASHAP - Rituximab 375 / Doxorubicin 10 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, diffuse large B-non-Hodgkin Lymphoma (PID359 V1.3)R-CHOEP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Etoposide 100 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID722 V1.0)R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 1-6 (PID112 V1.1)R-CHOP 14 - Rituximab 375, diffuse large B-non-Hodgkin Lymphoma, cycle 7-8 (PID1448 V1.0)R-CHOP 21 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID113 V1.2)R-COMP 21 - Rituximab 375 / Cyclophosphamide 750 / Vincristine 2 / lip. doxorubicin 50 / Prednisolone 100, diffuse large B-cell lymphoma (PID125 V1.0)R-CPOP 21 - Rituximab 375 / Cyclophosphamide 750 / Pixantron 88 / Vincristine 2 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID931 V1.0)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345 V1.0)R-DHAP - Rituximab 375 / Cisplatin 100 / Cytarabine 2000 / Dexamethasone 40, diffuse large B-non-Hodgkin Lymphoma (PID350 V1.2)R-ESHAP - Rituximab 375 / Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 250, diffuse large B-non-Hodgkin Lymphoma (PID358 V1.1)R-miniCHOP - Rituximab 375 / Cyclophosphamide 400 / Doxorubicin 25 / Vincristine 1 / Prednisolone 40, diffuse large B-non-Hodgkin Lymphoma (PID339 V1.2)Rituximab 1400, single dose subcutaneous (PID310 V2.0)Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, B-non-Hodgkin Lymphoma (PID354 V1.0)SMARTE- R-CHOP 14 - Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 2,4,6 (PID929 V1.0)SMARTE- R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID926 V1.0)SMARTE- R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma, cycle 3.5 (PID930 V1.0)SMARTE- R-CHOP 14 - Rituximab 375, diffuse large B-non-Hodgkin Lymphoma, cycle 7+ (PID75 V1.0)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972 V1.0)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968 V1.2)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970 V1.2)Study - Level - Nivolumab 240 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID967 V1.2)Study - level - Nivolumab 240 / Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID969 V1.2)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971 V1.1)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 1 (PID973 V1.0)Study - Level - Rituximab 375 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-non-Hodgkin Lymphoma, Cycle 2+ (PID974 V1.0)Study - OPTIMAL - Arm F-A, R-CHOP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1124 V1.0)Study - OPTIMAL - Arm F-B, R-CHLIP 14 - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine Liposomal 2 / Prednisolone 100, diffuse large B-non-Hodgkin Lymphoma (PID1123 V1.0)Vincristine 1 / Prednisolone 100, Pre-phase, diffuse large B-non-Hodgkin Lymphoma (PID69 V1.1)
